Therefore, the control of receptor Y by PYY becomes an attractive mechanism for the therapeutic management of obesity and its associated morbidities such as insulin resistance and diabetic dyslipidemia. The gene discussed is PYY; the disease is obesity due to melanocortin 4 receptor deficiency.